228 related articles for article (PubMed ID: 29031179)
1. Carbosilane metallodendrimers based on copper (II) complexes: Synthesis, EPR characterization and anticancer activity.
Sanz Del Olmo N; Maroto-Díaz M; Gómez R; Ortega P; Cangiotti M; Ottaviani MF; de la Mata FJ
J Inorg Biochem; 2017 Dec; 177():211-218. PubMed ID: 29031179
[TBL] [Abstract][Full Text] [Related]
2. Elaborated study of Cu(II) carbosilane metallodendrimers bearing substituted iminopyridine moieties as antitumor agents.
Carloni R; Sanz Del Olmo N; Canonico B; Montanari M; Ciacci C; Ambrosi G; de la Mata FJ; Ottaviani MF; García-Gallego S
Eur J Med Chem; 2021 Apr; 215():113292. PubMed ID: 33631696
[TBL] [Abstract][Full Text] [Related]
3. Antiviral properties against HIV of water soluble copper carbosilane dendrimers and their EPR characterization.
Galan M; Sanchez-Rodriguez J; Cangiotti M; Garcia-Gallego S; Jimenez JL; Gomez R; Ottaviani MF; Munoz-Fernandez MA; de la Mata FJ
Curr Med Chem; 2012; 19(29):4984-94. PubMed ID: 22963631
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes.
Maroto-Díaz M; Elie BT; Gómez-Sal P; Pérez-Serrano J; Gómez R; Contel M; Javier de la Mata F
Dalton Trans; 2016 Apr; 45(16):7049-66. PubMed ID: 26990859
[TBL] [Abstract][Full Text] [Related]
5. Cyclopentadienyl ruthenium(II) carbosilane metallodendrimers as a promising treatment against advanced prostate cancer.
Sanz Del Olmo N; Bajo AM; Ionov M; García-Gallego S; Bryszewska M; Gómez R; Ortega P; de la Mata FJ
Eur J Med Chem; 2020 Aug; 199():112414. PubMed ID: 32438200
[TBL] [Abstract][Full Text] [Related]
6. Organometallic dendrimers based on Ruthenium(II) N-heterocyclic carbenes and their implication as delivery systems of anticancer small interfering RNA.
Rodríguez-Prieto T; Michlewska S; Hołota M; Ionov M; de la Mata FJ; Cano J; Bryszewska M; Gómez R
J Inorg Biochem; 2021 Oct; 223():111540. PubMed ID: 34273717
[TBL] [Abstract][Full Text] [Related]
7. Fine-Tuning the Interaction and Therapeutic Effect of Cu(II) Carbosilane Metallodendrimers in Cancer Cells: An
Canonico B; Carloni R; Sanz Del Olmo N; Papa S; Nasoni MG; Fattori A; Cangiotti M; de la Mata FJ; Ottaviani MF; García-Gallego S
Mol Pharm; 2020 Jul; 17(7):2691-2702. PubMed ID: 32484691
[TBL] [Abstract][Full Text] [Related]
8. Regulating the anticancer properties of organometallic dendrimers using pyridylferrocene entities: synthesis, cytotoxicity and DNA binding studies.
Govender P; Riedel T; Dyson PJ; Smith GS
Dalton Trans; 2016 Jun; 45(23):9529-39. PubMed ID: 27193373
[TBL] [Abstract][Full Text] [Related]
9. Insight into the antitumor activity of carbosilane Cu(ii)-metallodendrimers through their interaction with biological membrane models.
Sanz Del Olmo N; Carloni R; Bajo AM; Ortega P; Fattori A; Gómez R; Ottaviani MF; García-Gallego S; Cangiotti M; de la Mata FJ
Nanoscale; 2019 Jul; 11(28):13330-13342. PubMed ID: 31271405
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Anticancer Properties of Copper Metallodendrimers.
Hołota M; Magiera J; Michlewska S; Kubczak M; Del Olmo NS; García-Gallego S; Ortega P; de la Mata FJ; Ionov M; Bryszewska M
Biomolecules; 2019 Apr; 9(4):. PubMed ID: 31003561
[TBL] [Abstract][Full Text] [Related]
11. Antibacterial Effect of Carbosilane Metallodendrimers in Planktonic Cells of Gram-Positive and Gram-Negative Bacteria and
Llamazares C; Sanz Del Olmo N; Ortega P; Gómez R; Soliveri J; de la Mata FJ; García-Gallego S; Copa-Patiño JL
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31450779
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Interactions of Ruthenium (II) Carbosilane Metallodendrimers and Precursors with Model Cell Membranes through a Dual Spin-Label Spin-Probe Technique Using EPR.
Carloni R; Sanz Del Olmo N; Ortega P; Fattori A; Gómez R; Ottaviani MF; García-Gallego S; Cangiotti M; de la Mata FJ
Biomolecules; 2019 Sep; 9(10):. PubMed ID: 31569790
[TBL] [Abstract][Full Text] [Related]
13. Original multivalent copper(II)-conjugated phosphorus dendrimers and corresponding mononuclear copper(II) complexes with antitumoral activities.
El Brahmi N; El Kazzouli S; Mignani SM; Essassi el M; Aubert G; Laurent R; Caminade AM; Bousmina MM; Cresteil T; Majoral JP
Mol Pharm; 2013 Apr; 10(4):1459-64. PubMed ID: 23410260
[TBL] [Abstract][Full Text] [Related]
14. Copper (II) complexes possessing alkyl-substituted polypyridyl ligands: Structural characterization and in vitro antitumor activity.
Angel NR; Khatib RM; Jenkins J; Smith M; Rubalcava JM; Le BK; Lussier D; Chen ZG; Tham FS; Wilson EH; Eichler JF
J Inorg Biochem; 2017 Jan; 166():12-25. PubMed ID: 27815978
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, crystal structure, and cytotoxic activity of novel cyclic systems in [1,2,4]thiadiazolo[2,3-a]pyridine benzamide derivatives and their copper(II) complexes.
Adhami F; Safavi M; Ehsani M; Ardestani SK; Emmerling F; Simyari F
Dalton Trans; 2014 Jun; 43(21):7945-57. PubMed ID: 24715093
[TBL] [Abstract][Full Text] [Related]
16. Transition metal complexes of neocryptolepine analogues. Part I: synthesis, spectroscopic characterization, and invitro anticancer activity of copper(II) complexes.
Emam SM; El Sayed Iel T; Nassar N
Spectrochim Acta A Mol Biomol Spectrosc; 2015 Mar; 138():942-53. PubMed ID: 24867072
[TBL] [Abstract][Full Text] [Related]
17. Coordination behavior of tetraaza [N₄] ligand towards Co(II), Ni(II), Cu(II), Cu(I) and Pd(II) complexes: synthesis, spectroscopic characterization and anticancer activity.
El-Boraey HA
Spectrochim Acta A Mol Biomol Spectrosc; 2012 Nov; 97():255-62. PubMed ID: 22765944
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drug.
Michlewska S; Kubczak M; Maroto-Díaz M; Sanz Del Olmo N; Ortega P; Shcharbin D; Gomez Ramirez R; Javier de la Mata F; Ionov M; Bryszewska M
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31450702
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structural characterization of copper(I) complexes bearing N-methyl-1,3,5-triaza-7-phosphaadamantane (mPTA): cytotoxic activity evaluation of a series of water soluble Cu(I) derivatives containing PTA, PTAH and mPTA ligands.
Porchia M; Benetollo F; Refosco F; Tisato F; Marzano C; Gandin V
J Inorg Biochem; 2009 Dec; 103(12):1644-51. PubMed ID: 19822369
[TBL] [Abstract][Full Text] [Related]
20. Syntheses, DNA binding and anticancer profiles of L-glutamic acid ligand and its copper(II) and ruthenium(III) complexes.
Ali I; Wani WA; Saleem K; Wesselinova D
Med Chem; 2013 Feb; 9(1):11-21. PubMed ID: 22741786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
